Outcomes in participants with ventilated nosocomial pneumonia and organ failure treated with ceftolozane/tazobactam versus meropenem: a subset analysis of the phase 3, randomized, controlled ASPECT-NP trial
Abstract Background The pivotal ASPECT-NP trial showed ceftolozane/tazobactam was non-inferior to meropenem for the treatment of ventilated hospital-acquired/ventilator-associated bacterial pneumonia (vHABP/VABP). Here, we evaluated treatment outcomes by degree of respiratory or cardiovascular dysfu...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
SpringerOpen
2023-02-01
|
Series: | Annals of Intensive Care |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13613-022-01084-8 |